Docetaxel and hyperthermia: Factors that modify thermal enhancement

Mohamed, Faheez; Stuart, O. Anthony; Gléhen, Olivier; Urano, Muneyasu; Sugarbaker, Paul H.

doi:10.1002/jso.20117

Cited by 37 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Docetaxel blocks the cell cycle in the G 2 /M phase. 15,23 Lokeshwar et al 16 demonstrated that 80% of all tumor cells are blocked in the G 2 /M phase 24 h after the administration of i.p. paclitaxel in Dunning tumors implanted in Copenhagen rats.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Paparel

Chapelon

Bissery

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to evaluate mechanisms of the synergy between high intensityfocused ultrasound (HIFU) and docetaxel and to determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth. A total of 15 days after s.c. implantation of the tumor, 52 Copenhagen rats studied were randomized in 4 groups of 13: controls, docetaxel alone (group 1), HIFU and docetaxel concomitant (group 2) and HIFU and docetaxel administered 24 h before treatment (group 3). The number of HIFU shots was calculated in order to cover 75% of the tumor volume. The effects of docetaxel, HIFU and their interaction on tumor volumes were analyzed using a linear regression. The distributions of the tumor volumes were significantly greater in the control group than in the group 1 (P ¼ 0.002) and than in both groups 2 and 3 (Po0.0001 and P ¼ 0.0001). These volumes were also significantly greater in group 1 than in both groups 2 and 3 and there was no difference between the groups 2 and 3. The tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls. The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel, the percentage of complete remission was approximately 30%.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Treatment with HIFU acts on tumor cells weakened by chemotherapy. 5,23 The hyperthermia that is generated by the HIFU is produced 24 h after the administration of docetaxel which has a half-life of a few hours; it therefore has little influence on the intracellular penetration of the chemotherapy in this group.…”

Section: Discussionmentioning

confidence: 99%

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Paparel

Chapelon

Bissery

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Tf has been reported to increase a cellular uptake of gold nanoparticles [18] and Doc has been reported to have a hyperthermia-enhanced cytotoxicity. [37] To evaluate and compare the in vitro cytotoxicity of Doc, pGSNs and pGSNs loading Doc (abbreviated hereinafter as pGSNs-Doc), and active targeting pGSNs loading Doc (abbreviated hereinafter as pGSNs-Doc-Tf) under NIR light irradiation, the viability of cells was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. To exclude the possible influence of pGSNs and pGSNs-Tf on MCF-7 cell viability, various concentrations of pGSNs were incubated with MCF-7 cells for 72 h and then cell viability was assessed.…”

Section: Doi: 101002/adma201103343mentioning

confidence: 99%

Targeting Gold Nanoshells on Silica Nanorattles: a Drug Cocktail to Fight Breast Tumors via a Single Irradiation with Near‐Infrared Laser Light

et al. 2011

View full text Add to dashboard Cite

One of the current challenges in biomedicine is to develop safe and effective nanomedicines for selective tumor therapy. [1] Recently, near-infrared (NIR) light absorbing plasmonic nanomaterials have attracted intensive attention for their hyperthemia therapy to kill tumorigenic cells without damaging normal cells, such as gold nanorods, [2] gold nanocages, [3] Au x Ag 1-x dendrites, [4] gold nanoshells on polystyrene spheres, [5] assembled gold nanoparticles [6] and many multifunctional nanocomposites. [7] Our previous study reported a novel material of gold nanoshells on drug-loaded silica nanorattles which can combine the hyperthermia with chemotherapy to optimize cancer therapy whose synergistic effects are greater than the two individual treatments alone. [8] Despite the successful application of many gold-based NIR absorbing materials in cancer therapy, most studies of them rely on the passive targeting effect (the so-called enhanced permeability and retention, EPR effect) to direct nanocarriers at tumor sites through the enhanced permeability of tumor vasculature and the decreased draining efficacy of tumor lymphatics. [9,10] The lack of cell specific interactions may decrease the therapeutic efficacy and thus need a relatively long NIR light irradiation time (30 min in vitro, e.g.), [11] a high NIR laser light irradiation intensity (35 W cm -2 in vitro, e.g.), [12] or repeated injections and NIR laser light irradiations [8] as the previous reports. Furthermore, not all tumors exhibit EPR effect which can enhance the preferential accumulation of nanoparticles in the tumor. [13,14] For clinical applications, a more effective drug delivery strategy should be developed to promote the binding and internalization of nanocarrier through their specific interactions with the receptors expressed on the cell surface of interest. [15] Transferrin (abbreviated hereinafter as Tf) is one of the widely used targeting ligand. Because of rapid cell division and stringent demand for iron (for heme synthesis), many cancer cell types have abundant expression of Tf receptors (TfRs).[16] Tf has been used to enhance the cellular uptake of gold nanoparticles [17] and quantum dots/rods. [18] To the best of our knowledge, Tf-conjugated gold-based nanoparticles for both hyperthermia and chemotherapy of cancer cells have been rarely reported. Most importantly, there are few comparative studies on in vivo excretion/clearance, safety, and efficacy of targeted conjugated and non-conjugated nanotherapeutics, while elucidating these in vivo studies is considered very important regarding the safety and validity of novel nanocarrier systems. [19] In view of this pressing need for more efficient treatment modalities, we engineered a kind of Tf and PEG functionalized gold nanoshells on silica nanorattles (pGSNs-Tf) for ablation of breast carcinoma in the present study. We hypothesized that the targeting pGSNs-Tf can preferentially bind to breast cancer cells rather than normal cells and then increase the efficiency of thermo-chemotherapy ab...

show abstract

“…The sequence in which the treatment is applied (i.e. sequential vs. synchronous) appears also to be determinant for a therapeutic benefit [151][152][153][154]. Moreover, for a sequential heat-drug or drug-heat treatment the delay between them is also critical [155].…”

Section: Biologic Rationale For Hyperthermia In Combination With Chemmentioning

confidence: 99%

In situ forming implants for local chemotherapy and hyperthermia of bone tumors

Mohamed

Borchard

Jordan

2012

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Hyperthermia, an established adjuvant in cancer treatment, potentiates the effects of anticancer drugs and synergetic combination can be obtained improving the therapeutic outcome. Bone metastases may benefit from this combination when treated through in situ forming implants. Once loaded with magnetizable (nano-) particles and antineoplastic agents, these implants allow for the local application of magnetically-induced hyperthermia and the release of an anticancer drug. The implant can be heated applying an external magnetic field, sensitizing the surrounding tumoral tissues, while releasing the chemotherapeutic agent.Moreover, bone implants provide mechanical support to the weakened bone and consequently relieve pain.This review gives an overview of the current knowledge as well as the rationale of combining locally both magnetic hyperthermia and chemotherapy using in situ forming implants in the field of bone metastases treatment. KeywordsInduced hyperthermia, chemotherapy, drug delivery systems, in situ forming implants, iron oxide nanoparticles, bone metastases, cementoplasty, vertebroplasty 3

show abstract

Docetaxel and hyperthermia: Factors that modify thermal enhancement

Cited by 37 publications

References 33 publications

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Targeting Gold Nanoshells on Silica Nanorattles: a Drug Cocktail to Fight Breast Tumors via a Single Irradiation with Near‐Infrared Laser Light

In situ forming implants for local chemotherapy and hyperthermia of bone tumors

Contact Info

Product

Resources

About